ArticleInternational journal of molecular sciences2013
Materials characterization of Feraheme/ferumoxytol and preliminary evaluation of its potential for magnetic fluid hyperthermia.
Article in International journal of molecular sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- Article
- Protein Corona as a Result of Interaction of Protein Molecules with Inorganic Nanoparticles.International journal of molecular sciences · 2025Review
- Receptor-Mediated SPION Labeling of CD4Nanomaterials (Basel, Switzerland) · 2025Article
- Power-free plasma separation based on negative magnetophoresis for rapid biochemical analysis.Microsystems & nanoengineering · 2024Article
- Pharmacokinetic Profiling of Unlabeled Magnetic Nanoparticles Using Magnetic Particle Imaging as a Novel Cold Tracer Assay.Nano letters · 2024Article
- Magnetic Hyperthermia in Glioblastoma Multiforme Treatment.International journal of molecular sciences · 2024Review
- RETRACTED: Impact of High-Frequency Traveling-Wave Magnetic Fields on Low-Conductivity Liquids: Investigation and Potential Applications in the Chemical Industry.Materials (Basel, Switzerland) · 2024Article
- MRI Detection and Therapeutic Enhancement of Ferumoxytol Internalization in Glioblastoma Cells.Nanomaterials (Basel, Switzerland) · 2024Article
- Iron oxide nanoparticles as positive TScientific reports · 2023Article
- A magnetic hydrogel for the efficient retrieval of kidney stone fragments during ureteroscopy.Nature communications · 2023Article
- Theranostic Role of Iron Oxide Nanoparticle for Treating Renal Anemia: Evidence of Efficacy and Significance by MRI, Histology and Biomarkers.Pharmaceutics · 2023Article
- A review on microfluidic-assisted nanoparticle synthesis, and their applications using multiscale simulation methods.Discover nano · 2023Review
- Modulating the Surface Properties of Lithium Niobate Nanoparticles by Multifunctional Coatings Using Water-in-Oil Microemulsions.Nanomaterials (Basel, Switzerland) · 2023Article
- Cell sorting microbeads as novel contrast agent for magnetic resonance imaging.Scientific reports · 2022Article
- Targeted Delivery of DNA Topoisomerase Inhibitor SN38 to Intracranial Tumors of Glioblastoma Using Sub-5 Ultrafine Iron Oxide Nanoparticles.Advanced healthcare materials · 2022Article
- Current approaches of nanomedicines in the market and various stage of clinical translation.Acta pharmaceutica Sinica. B · 2022Review
- Oxidation of ferumoxytol by ionizing radiation releases iron. An electron paramagnetic resonance study.Journal of radiation research · 2022Article
- In vivo imaging of nanoparticle-labeled CAR T cells.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Ex Vivo and In Vivo Evaluation of Dodecaborate-Based Clusters Encapsulated in Ferumoxytol Nanoparticles.Langmuir : the ACS journal of surfaces and colloids · 2021Article
- One-pot synthesis of carboxymethyl-dextran coated iron oxide nanoparticles (CION) for preclinical fMRI and MRA applications.NeuroImage · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Feraheme, is a recently FDA-cleared superparamagnetic iron oxide nanoparticle (SPION)-based MRI contrast agent that is also employed in the treatment of iron deficiency anemia. Feraheme nanoparticles have a hydrodynamic diameter of 30 nm and consist of iron oxide crystallites complexed with a low molecular weight, semi-synthetic carbohydrate. These features are attractive for other potential biomedical applications such as magnetic fluid hyperthermia (MFH), since the carboxylated polymer coating affords functionalization of the particle surface and the size allows for accumulation in highly vascularized tumors via the enhanced permeability and retention effect. This work presents morphological and magnetic characterization of Feraheme by transmission electron microscopy (TEM), Energy dispersive X-ray spectroscopy (EDX), and superconducting quantum interference device (SQUID) magnetometry. Additionally, the results of an initial evaluation of the suitability of Feraheme for MFH applications are described, and the data indicate the particles possess promising properties for this application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.